Compass Pathways Plc ADR
Cerrado
12.49 -1.26
Resumen
Variación precio
24h
Mínimo
12.33
Máximo
13.48
Ingresos | 185M 91M |
|---|---|
BPA | -0.3 |
Empleados | 156 |
EBITDA | 139M 93M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +85.77% upside |
Próximas Ganancias | 30 jul 2026 |
|---|
Capitalización Mercado | 428M 1.7B |
|---|---|
Apertura anterior | 13.75 |
Cierre anterior | 12.49 |
Compass Pathways Plc ADR Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
